Prosecution Insights
Last updated: November 20, 2026
Application No. 17/802,794

ANTIGEN-PRESENTING EXTRACELLULAR VESICLES, COMPOSITION CONTAINING SAME, AND METHOD FOR PRODUCTION THEREOF

Final Rejection §101§102§112§DOUBLEPATENT
Filed
Aug 26, 2022
Priority
Feb 28, 2020 — JP 2020-033331 +1 more
Examiner
CHATTIN, AMY MARIE
Art Unit
1643
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nissan Chemical Corporation
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
40 granted / 56 resolved
+11.4% vs TC avg
Strong +46% interview lift
Without
With
+45.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
46 currently pending
Career history
104
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
32.1%
-7.9% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
32.4%
-7.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 56 resolved cases

Office Action

§101 §102 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims Status The Amendment filed on 01Jul2026 is acknowledged in which claim(s) 2-4, 9-11, 18-19, 27-28, and 35 were canceled, and claim(s) 48-63 are new. Applicant’s election without traverse of the invention of Group I (claims 1-31, 36-37, 39-46) in the reply filed on 27Oct2025 is acknowledged. Claims 32-34, 38, 47, 54, 63 is/are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 27Oct2025. Claim(s) 1, 5-8, 12-17, 20-26, 29-31, 36-37, 39-46, 48-53, 55-62 are presented for examination on the merits. Response to Amendment and Arguments All previous objection(s) have been withdrawn in view of the Amendment filed on 01Jul2026. All previous rejections and/or objections of claim(s) 2-4, 9-11, 18-19, 27-28 are moot in view of claim cancelation. The rejection(s) of claim(s) 1, 8, 31, 39-41, 45-46 under 35 U.S.C. § 101, and of claim(s) 1, 31, 39-41, 45-56 under 35 U.S.C. § 102 have been maintained in modified form in view of the recent claim amendment filed on 01Jul2026, which added new limitations not previously considered. The rejections are maintained for reasons provided in response to arguments below. The rejection(s) of claim(s) 26, 29; 5-7, 12-13, 17, 20-25, 30 under 35 U.S.C. § 112(a), of claim(s) 5-7, 13-17, 20-21, 29-30, 36-37 under 35 U.S.C. § 112(b), and of claim(s) 17, 20-26, 29-30, under 35 U.S.C. § 112(d), under 35 U.S.C. § 112(b) have been withdrawn in view of the recent claim amendment filed on 01Jul2026. The previous rejection(s) of claim(s) 1, 5-8, 12-17, 20-26, 29-31, 36-37, 49-46, 48-53, 55-62 under nonstatutory double patenting have been maintained in modified form for reasons provided in response to arguments below. New rejection(s) and/or objections were necessitated by claim amendments filed on 01Jul2026 (see below for details). MAINTAINED & NEW REJECTIONS/OBJECTIONS AS NECESSITATED BY CLAIM AMENDMENTS Claim Interpretation Claim(s) 1, 5-8, 12-17, 20-26, 29-31, 36-37, 39-46, 48-53, 55-62 recite(s) the limitation "…is capable of presenting the antigen on the T-cell costimulatory molecule outside membrane…" in lines 4-5 of claim 1(A) and “…is capable of presenting the antigen-presenting MHC molecule and the T-cell stimulatory cytokine outside membrane…” in lines 12-13 of claim 17. The instant specification does not define which molecule(s) are capable of presenting the antigen (e.g., claim 1) and/or antigen-presenting MHC molecule and T cell stimulatory cytokine (e.g., claim 17) on the respective T-cell outside membrane. The broadest reasonable interpretation (BRI) of the above phrases are considered to mean any fusion protein or protein complex comprising an MHC molecule (e.g., claims 1, 17) and/or any T cell stimulatory cytokine (claim 17). Claim Objections Claim(s) 1, 5-8, 12-17, 20-26, 29-31, 36-37, 39-46, 48-53, 55-62 is/are objected to because of the following informalities: “…or transmembrane domains thereof…” should be “…or transmembrane domain[[s]] thereof…” in lines 2-3 of claim 1(A), and line 9 of claim 17. Appropriate correction is required. Claim(s) 17, 20-26, 29-30, 49-53, 55-62, is/are objected to because of the following informalities: “…comprises (D) a fusion protein which comprises…” should be “…comprises [[(D)]] a fusion protein which comprises…” in line 5 because there is/are no (A)-(C). Appropriate correction is required. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claim(s) 1, 8, 31, 36-37, 39-46, 48 is/are rejected under 35 U.S.C. 101 because the claimed invention is directed to a product of nature (natural phenomenon) without significantly more. Claim(s) 1, 8, 31, 36-37, 39-46, 48 is/are evaluated using the “Subject Matter Eligibility Test for Products and Processes” flow chart as shown in MPEP § 2106 (III). Step 1: Is the claim to a process, machine, manufacture or composition of matter? Yes. The claim(s) is/are drawn to a composition which is one of the four statutory categories. Step 2A, Prong One: Does the claim recite an abstract idea, law of nature, or natural phenomenon? Yes. The claim(s) is/are directed towards a natural phenomenon because the claims require an antigen-presenting extracellular vesicle (EV) presenting an antigen-presenting MHC molecule, a T cell stimulatory cytokine, and a T cell costimulatory molecule outside of the EV membrane (e.g., extracellular T cell costimulatory molecule; see 112b rejection above for details). As previously discussed in the Office Action mailed on 03Mar2026, Viaud et al. 2009 (PloS one, 4(3), e4942; reference of record) teaches that naturally occurring exosomes produced by dendritic cells comprise functional MHC/peptide complexes as well as functional IL-15Ra [e.g., abstract] capable of binding and trans-presenting the cytokine IL-15 [e.g., fig. 3], which is naturally present in abundance in vivo [e.g., pg. 8, last ¶ ]. Dimitris et al. 2002 (Molecular immunology, 38(16-18), 1359-1362; reference of record) and Shelke et al. 2019 (Journal of extracellular vesicles, 8(1), 1650458; reference of record), respectively, teach that naturally occurring exosomes produced by mast cells contain MHC/peptide complexes and TGF-β. Further, Levy and Shoham 2005 (Nature Reviews Immunology, 5(2), 136-148; reference of record) teaches that exosomes can further comprise the costimulatory molecules CD80 or CD86 alongside MHC class II in complex with tetraspanin CD81. Accordingly, an exosome (e.g., a type of extracellular vesicle) comprising an antigen-presenting MHC molecule (e.g. MHC/peptide) and a T-cell stimulatory cytokine (e.g. IL-15 or TGF-β) and a costimulatory protein (e.g. CD80, CD86) wherein the cytokine is presented outside the membrane of the vesicle and capable of interacting with T cells (as would be the case in for membrane-bound IL-15Ra in complex with and trans-presenting naturally occurring IL-15) is the natural phenomenon. Step 2A, Prong Two: Does the claim recite additional elements that integrate the judicial exception into a practical application? No. Specifically, claim 1 does not recite any additional structural elements sufficient to differentiate the claimed EVs from their naturally occurring counterparts and therefore do not integrate the judicial exception into a practical application. Step 2B: Does the claim recite additional elements that amount to significantly more than the judicial exception? No. The judicial exception recite in claim 1 is recited without additional limitations (e.g., additional elements) amounting to significantly more than the exception. Specifically, claim 1 is drawn to a naturally occurring EV and characteristics thereof (e.g., MHC/peptide, mbIL15, CD80; see above for details). A skilled artisan, as evidenced by the prior art recited above, would understand how to identify said naturally occurring EV population of the instant invention, and it is noted that well-understood, routine and conventional limitations are not enough to qualify as reciting something "significantly more" than the judicial exception(s) (see MPEP 2106.04(d)). Claim(s) 8, 31, 36-37, 39-46, 48, which depend from claim 1, act to further limit the cytokine species; EV species; membrane protein and membrane binding protein species; process for obtaining EVs; pharmaceutical compositions comprising the EVs; and/or pharmaceutical compositions comprising the EVs for treating one of a variety of indication(s). Well-understood, routine and conventional limitations are not enough to qualify the claimed method as reciting something "significantly more" than the judicial exception(s) (see MPEP 2106.04(d)). In the instant case, a "pharmaceutical composition" - examples of which according to ¶0198 of the instant specification include a solvent or buffer - does not convey any structural or functional difference to the claimed exosomes relative to their natural counterpart. Indeed, dendritic cell derived exosomes containing MHC II molecules and costimulatory proteins are already in use in clinical trials (Besse et al. 2016, Oncoimmunology, 5(4), e1071008; reference of record), and their preparation as a "pharmaceutical composition" would be routine and conventional to one of ordinary skill in the art. The limitations do not amount to significantly more than the judicial exception. As the instant claim(s) 1, 8, 31, 36-37, 39-46, 48 recite judicial exceptions not integrated into a practical application, and no elements that amount to significantly more than the judicial exception are recited, the claims were found not to be drawn to eligible subject matter under 35 USC § 101. Response to Arguments Applicant argues, in summary, that the amended claims are directed to patent-eligible subject matter because the claims recite that the extracellular vesicles comprise either (1) components (A), (B), and (C) or (2) component (D), wherein at least components (A), (B), and (D) are artificial fusion proteins. The artificial fusion proteins are structurally different from the naturally occurring exosome components described by the Office, and, as such, claims 1, 8, 31, 39-41, 45, and 46 are directed to significantly more than a product of nature. Accordingly, the section 101 rejection should be withdrawn. In response, the broadest reasonable interpretation (BRI) of instant claim 1 does not require artificial fusion proteins. For example, the BRI of ‘(A)’ includes a complex comprising (1) MHC and an extracellular vesicle (EV) membrane protein or transmembrane domain thereof, or (2) an EV membrane binding protein or a membrane binding domain thereof; the BRI of ‘(B)’ includes (1) a fusion protein comprising a T cell stimulatory cytokine or submit thereof and an EV membrane protein or transmembrane domain thereof, or (2) an EV membrane binding protein or a membrane binding domain thereof; and the BR of ‘(C)’ includes any protein comprising a T cell costimulatory molecule capable of presenting said molecule on the outside membrane (e.g., including MHC/peptide complexes, see claim interpretation above). Therefore, the BRI of instant claim 1 is not considered to require ‘artificial fusion proteins’. Lastly, Applicant recited ‘(D)’ is not recited in independent claim 1, rather only applicant claim 17, and claims dependent therefrom recite ‘(D)’, and it is noted that those claim(s) requiring ‘(D)’ are not included in the current 101 rejections (see above for details). Applicant arguments have been thoroughly reviewed but are not persuasive. The rejection(s) of claim(s) 1, 8, 31, 36-37, 39-46, 48 are maintained in modified form. Claim Rejections - 35 USC § 112(b) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claim(s) 1, 5-8, 12-17, 20-26, 29-31, 36-37, 39-46, 48-53, 55-62 is/are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim(s) 1, 5-8, 12-16, 31, 36-37, 39-46, 48, recite(s) “…a T-cell costimulatory molecule outside membrane…” in line(s) 2-4 of claim 1, rendering the claim(s) indefinite. The instant specification does not provide a definition of the phrase above, and it is not grammatically clear. Specifically, it is unclear if the phrase above (1) is missing one or more words between “a T-cell costimulatory molecule” and “outside membrane”; (2) means the EV membrane comprises T-cell costimulatory molecules; (3) means T-cell costimulatory molecules that exist outside of the EV (e.g., in the interstitial space, TME, etc.); or (4) something else. For the purposes of compact prosecution, the phrase will be considered to mean any T cell costimulatory factor outside of the EV. This rejection may be overcome by amending claim(s) 1 as recited above or to otherwise clearly recite the limitation(s) of the instant invention. Claim(s) 5-8, 12-16, 31, 36-37, 39-46, 48 can overcome this rejection by amending claim(s) 1 as recited above. Claim(s) 1, 5-8, 12-16, 31, 36-37, 39-46, 48, recites the limitation "…the antigen on the T-cell…" in lines 4-5 of claim 1(A). There is insufficient antecedent basis for this limitation in the claim. Specifically, claim 1 recites ‘an antigen-presenting extracellular vesicle’ in line 1 and ‘an antigen-presenting MHC molecule” in line 2, respectively; but fails to provide antecedent basis for ‘the antigen’ in the phrase recited above. For the purposes of compact prosecution, the phrase "… the antigen on the T-cell…" is considered to mean any antigen. Claim(s) 17, 20-26, 29-30, 49-53, 55-62, recite(s) “…a T-cell costimulatory molecule outside membrane…” in line(s) 2-4 of claim 1, rendering the claim(s) indefinite. The instant specification does not provide a definition of the phrase above, and it is not grammatically clear. Specifically, it is unclear if the phrase above (1) is missing one or more words between “a T-cell costimulatory molecule” and “outside membrane”; (2) means the EV membrane comprises T-cell costimulatory molecules; (3) means T-cell costimulatory molecules that exist outside of the EV (e.g., in the interstitial space, TME, etc.); or (4) something else. For the purposes of compact prosecution, the phrase will be considered to mean any T cell costimulatory factor outside of the EV. This rejection may be overcome by amending claim(s) 1 as recited above or to otherwise clearly recite the limitation(s) of the instant invention. Claim(s) 5-8, 12-17, 20-26, 29-31, 36-37, 39-46, 48-53, 55-62 can overcome this rejection by amending claim(s) 1 as recited above. Claim(s) 36-37, recites “A culture supernatant obtained by culturing the cell according to claim 34.” in claim 36, and “An antigen-presenting extracellular vesicle obtained from the culture supernatant according to claim 36.” in claim 37, rendering the claim(s) indefinite. Specifically, claim 34 has been withdrawn for being drawn to the unelected invention and is not examined on the merits herein. Further, the elected invention is a product, and claims 36-37 are the product of claim 1 as produced by a specific process. Therefore, for the purposes of compact prosecution, claims 36-37 will be considered product by process type claims relative to the product of claim 1 (see MPEP 2113). This rejection may be overcome by amending claim(s) 36-37 to depend from a claim of the elected invention. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim(s) 1, 31, 36-37, 39-41, 45-46, 48 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kim et al. 2018 (WO 2018/101782 A1; IDS dated 8/26/2022). Note: US 2020/0071668 A1 is used as the English translation for WO 2018/101782 A1, and all references made herein are to US 2020/0071668 A1. Regarding instant claims 1, 31, 48, Kim teaches exosomes expressing the cytokine 4-1BBL [e.g., abstract; ¶ 0004, 0006, 0020, 0023-0025, 0032] as well as (A) membrane bound peptide-MHC complex (e.g., an antigen-presenting MHC molecule; an extracellular protein complex comprising MHC and a membrane protein; see 112b rejection above for details) [e.g., title, abstract; ¶ 0002, 0025]; (B) ICAM (e.g., an extracellular vesicle membrane binding protein) [e.g., ¶ 0036, 0091-0092]; and (C) T cell costimulatory proteins including CD32, CD80, and CD83 [e.g., abstract; ¶ 0023-0031, 0081; fig. 1c;]. Regarding instant claim 8, 36-37, Kim further teaches extravesicular IL2 (e.g., T cell stimulatory cytokine outside of the exosome) for exosome and T cell co-culture (e.g., supernatant comprising the exosome) [e.g., ¶ 0061, 0063, 0077, 0085], and the collection of the exosome pellets therefrom (e.g., extracellular vesicles obtained from supernatant [e.g., ¶ 0077]. Regarding Claims 39-41, 45, Kim teaches “...the present invention provides a vaccine for preventing tumors, pathogen infections or autoimmune diseases, or a pharmaceutical composition for treating tumors, pathogen infections, or autoimmune diseases including the exosome” [e.g., ¶ 0050]. Regarding Claims 46, the limitation recited in the preamble (e.g. “...for treating or preventing an allergic disease...”) is directed to an intended use and does not require additional structural elements that differentiate the claimed pharmaceutical composition from that of the prior art. Response to Arguments Applicant argues, in summary, that the features of claim 10 (not previously rejected under 102) has been incorporated into claim 1 and therefore claim 1 should now overcome the 102. In response, claims 10 of the previously examined claim set filed on 08/26/2022 recited “The antigen-presenting extracellular vesicle according claim 1, the member of which contains a fusion protein which contains a T-cell costimulatory molecule, and a membrane protein capable of being expressed…”, wherein amended claim 1 under consideration in this Office Action recites “…(A) a fusion protein or a protein complex…(B) a fusion protein which comprises… or transmembrane protein thereof; or an extracellular vesicle membrane binding protein….(C) a protein…”. Therefore the BRI of claim 10 that was canceled by Applicant specifically required a fusion protein, whereas the amended claim 1 as written does not require a fusion protein for any of the instant limitations. Accordingly, the 102 rejection has been re-written to meet the new limitations of the currently amended claim set. Applicant arguments have been thoroughly reviewed but are not persuasive. The rejection(s) of claim(s) 1, 31, 36-37, 39-41, 45-46, 48 are maintained in modified form. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 5-8, 12-17, 20-26, 29-31, 36-37, 39-46, 48-53, 55-62 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over: claims 1-38 of copending Application No. 17/802,871 claims 1-57 of copending Application No. 18/687,485 Although the claims at issue are not identical, they are not patentably distinct from each other because: The claims of ‘871 and ‘485 are drawn to polynucleotides encoding fusion proteins comprising antigen-presenting MHC molecules, T cell stimulatory cytokines, and/or T-cell costimulatory molecules wherein the fusion proteins are expressed “outside membrane of an extracellular vesicle”. The claims of ‘871 and ‘485 are further drawn to each of the particular fusion protein architectures of the instant claims (e.g. ‘871 claims 5, 7, 10, 12, 18, 21-24; ‘485 claims 8-15, 20-23, 28, 32-35), the particular species of cytokines (‘871 claim 15; ‘485 claim 24), and pharmaceutical compositions (‘871 claims 33-37; ‘485 claims 52-56). ‘871 claim 38 and ‘485 claim 57 are drawn in part to a method of producing antigen-presenting extracellular vesicles comprising introducing the claimed polynucleotides into cells. The claims of ‘871 and ‘485 are not drawn directly to the extracellular vesicles themselves, however, it would have been prima facie obvious to one of ordinary skill in the art that the claims of ‘871 and ‘485 could further comprise extracellular vesicles comprising the fusion proteins expressed by the claimed polynucleotides. There would have been a reasonable expectation of success because the claims of ‘871 and ‘485 are drawn to a method of producing such extracellular vesicles. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Response to Arguments Applicant argues, in summary, that the obviousness-type double patenting rejections are provisional in nature because the '871 application and the '485 application remain pending. Applicant requests that the obviousness-type double patenting rejections be held in abeyance until the present application otherwise is in condition for allowance. In response, MPEP 804(I)(B)(1) “A complete response to a nonstatutory double patenting (NSDP) rejection is either a reply by applicant showing that the claims subject to the rejection are patentably distinct from the reference claims, or the filing of a terminal disclaimer in accordance with 37 CFR 1.321 in the pending application(s) with a reply to the Office action (see MPEP § 1490 for a discussion of terminal disclaimers). Such a response is required even when the nonstatutory double patenting rejection is provisional…”. Applicant did not show that the claims are patentably distinct, nor file a terminal disclaimer (e.g., the two options provided by the MPEP as recited above). Applicant did not provide any specific arguments and therefore are not persuasive. The rejection(s) of claim(s) 1, 5-8, 12-17, 20-26, 29-31 ,36-37 , 39-46, 48-53, 55-62 are maintained in modified form. Conclusion No claims are currently allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMY M CHATTIN whose telephone number is (571)270-0646. The examiner can normally be reached T-F 0600-1600 PST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at (571) 272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AMY M. CHATTIN/Examiner, Art Unit 1643 /GARY B NICKOL/Primary Examiner, Art Unit 1643
Read full office action

Prosecution Timeline

Aug 26, 2022
Application Filed
Oct 21, 2025
Applicant Interview (Telephonic)
Oct 21, 2025
Examiner Interview Summary
Mar 03, 2026
Non-Final Rejection mailed — §101, §102, §112
Jul 01, 2026
Response Filed
Oct 19, 2026
Final Rejection mailed — §101, §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797452
METHODS TO STIMULATE IMMUNE RESPONSES TO MUTANT RAS USING ANUCLEATE CELLS
3y 9m to grant Granted Nov 17, 2026
Patent 12797415
SYNTHETIC ANTIGENS AS CHIMERIC ANTIGEN RECEPTOR (CAR) LIGANDS AND USES THEREOF
3y 7m to grant Granted Nov 17, 2026
Patent 12799226
IMPROVED ANTIGEN BINDING RECEPTORS
3y 6m to grant Granted Nov 17, 2026
Patent 12782357
ANTIBODIES THAT BIND TO LRP5 PROTEINS AND METHODS OF USE
4y 8m to grant Granted Nov 03, 2026
Patent 12753229
COMPOSITIONS AND METHODS FOR MODULATING FLRT3 MEDIATED SIGNAL TRANSDUCTION
3y 9m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+45.9%)
3y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 56 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month